The safety of tumor necrosis factor-alpha (TNF-α) inhibitors in the setting of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is controversial. The use of anti-TNF-α in rheumatoid arthritis (RA) is associated with an increased risk of hepatitis re-activation. This paper reports experience of using etanercept and adalimumab in 32 patients with RA and previous HBV or HCV infection. No cases of HBV or HCV reactivation were seen. In just over a fifth of patients, increased transaminases levels were seen, which were associated with concomitant use of disease-modifying antirheumatic drugs, isoniazid prophylaxis, or alcohol abuse. In our experience, anti-TNF-α therapy appears to be safe in RA patients with previous HBV or HCV infection, but monitoring remains necessary in these patients.

Ballanti, E., Conigliaro, P., Chimenti, M.s., Kroegler, B., DI MUZIO, G., Guarino, M.d., et al. (2014). Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. DRUG DEVELOPMENT RESEARCH, 75, S42-S45 [10.1002/ddr.21193].

Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients

BALLANTI, ELEONORA;CONIGLIARO, PAOLA;CHIMENTI, MARIA SOLE;DI MUZIO, GIOIA;GUARINO, MARIA DOMENICA;Triggianese, P;PERRICONE, ROBERTO
2014-01-01

Abstract

The safety of tumor necrosis factor-alpha (TNF-α) inhibitors in the setting of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is controversial. The use of anti-TNF-α in rheumatoid arthritis (RA) is associated with an increased risk of hepatitis re-activation. This paper reports experience of using etanercept and adalimumab in 32 patients with RA and previous HBV or HCV infection. No cases of HBV or HCV reactivation were seen. In just over a fifth of patients, increased transaminases levels were seen, which were associated with concomitant use of disease-modifying antirheumatic drugs, isoniazid prophylaxis, or alcohol abuse. In our experience, anti-TNF-α therapy appears to be safe in RA patients with previous HBV or HCV infection, but monitoring remains necessary in these patients.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/16 - Reumatologia
English
Con Impact Factor ISI
anti-TNF; hepatitis B; hepatitis C; rheumatoid arthritis; Aged; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Aspartate Aminotransferases; Comorbidity; Female; Hepatitis B; Hepatitis C; Humans; Immunoglobulin G; Italy; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Retrospective Studies; Tumor Necrosis Factor-alpha
Ballanti, E., Conigliaro, P., Chimenti, M.s., Kroegler, B., DI MUZIO, G., Guarino, M.d., et al. (2014). Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. DRUG DEVELOPMENT RESEARCH, 75, S42-S45 [10.1002/ddr.21193].
Ballanti, E; Conigliaro, P; Chimenti, Ms; Kroegler, B; DI MUZIO, G; Guarino, Md; Triggianese, P; Gigliucci, G; Novelli, L; Barbato, C; Perricone, R
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Use of Anti-Tumor Necrosis Factor Alpha Therapy in.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 59.75 kB
Formato Adobe PDF
59.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/119009
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
social impact